Sign In
Buy BNTX
$90.62
+0.430 (+0.477%)
At Close: Jun 23, 2026
Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO
02:38am, Wednesday, 17'th Jun 2026
U.S. pharmaceutical company Moderna is interested in investing in production facilities in Germany, with an eye on plants that its German rival BioNTech plans to close, CEO Stepha
Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study
12:55pm, Thursday, 04'th Jun 2026
Arcus Biosciences teams up with Bristol Myers Squibb to test casdatifan combinations in kidney cancer, expanding its ccRCC development strategy.
Bristol Myers Showcases Data on MM and NSCLC Drugs at ASCO
11:01am, Monday, 01'st Jun 2026
BMY unveils strong ASCO data for mezigdomide and pumitamig, highlighting late-stage pipeline progress across myeloma and lung cancer.
First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer acros
BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
05:00am, Friday, 22'nd May 2026
Pumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to consistently show encouraging anti-tumor activity for pumitam
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026
04:15pm, Friday, 15'th May 2026
MAINZ, Germany, May 15, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) held its Annual General Meeting (“AGM”) today. A total of 92 per cent of the shar
BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM
12:10pm, Friday, 15'th May 2026
BioNTech NASDAQ: BNTX used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and a rest
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally
01:15pm, Wednesday, 13'th May 2026
The hantavirus isn't as contagious as the coronavirus, making a global pandemic unlikely. Picking the potential winners in the hantavirus vaccine market would hardly be worth the time and risk.
BioNTech Announces New ADS Repurchase Program
06:45am, Thursday, 07'th May 2026
MAINZ, Germany, May 7, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced that it has authorized a new share repurchase program (the “Program�
BioNTech Q3 Earnings Review: Getting Into The Weeds With Bewildering Oncology Plans
03:57pm, Wednesday, 06'th May 2026
BioNTech SE is downgraded to Sell due to declining COVID vaccine revenues, leadership exits, and pipeline uncertainty. BNTX faces €531.9m Q1 net loss, expects €2–3bn 2026 revenues, and plans €
Germany says vaccine supply secure despite BioNTech production loss
07:44am, Wednesday, 06'th May 2026
A German government spokesperson said on Wednesday that the loss of BioNTech vaccine production in the country can be offset by other companies.
BioNTech SE (BNTX) Q1 2026 Earnings Call Transcript
03:21pm, Tuesday, 05'th May 2026
BioNTech SE (BNTX) Q1 2026 Earnings Call Transcript
BioNTech Slides As Vaccine Sales Drop, Restructuring Plan Takes Shape
12:18pm, Tuesday, 05'th May 2026
Shares of BioNTech SE (NASDAQ:BNTX) are trading lower on Tuesday as the company reported mixed first-quarter financial results.
BioNTech to Close Sites, Cut Quarter of Workforce in Savings Push
07:26am, Tuesday, 05'th May 2026
The company said it would exit operations at some manufacturing plants in Germany and Singapore, as well as sites it acquired as part of its CureVac takeover.
BioNTech to close sites in Germany, Singapore affecting 1,860 staff
06:47am, Tuesday, 05'th May 2026
Germany's BioNTech said on Tuesday it would close sites affecting up to 1,860 jobs and buy back up to $1 billion worth of its shares, following the announcement of two co-founders quitting the C
